Epoprostenol
Back to searchMolecule Structure
Scientific Name
Epoprostenol
Description of the Drug
Epoprostenol is a vasodilator and platelet aggregation inhibitor used for the management of primary pulmonary hypertension and pulmonary hypertension in patients with heart failure.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01240
http://www.drugbank.ca/drugs/DB01240
Brand Name(s)
Not Available
Company Owner(s)
Actelion Pharmaceuticals Us Inc, Sun Pharmaceutical Industries Ltd, Glaxosmithkline Llc, Teva Pharmaceuticals Usa
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Prostanoid IP receptor | SINGLE PROTEIN | AGONIST | CHEMBL1995 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8041 | |||
| Human Metabolome Database | HMDB0001335 | |||
| DrugBank | DB01240 | |||
| PubChem: Thomson Pharma | 14900947 | |||
| PubChem | 5282411 | |||
| NMRShiftDB | 60020637 | |||
| Nikkaji | J17.550A | |||
| EPA CompTox Dashboard | DTXSID5022988 | |||
| LipidMaps | LMFA03010087 | |||
| DrugCentral | 1034 | |||
| Metabolights | MTBLC15552 | |||
| Brenda | 204317 | 29197 | 47566 | 6018 |
| Guide to Pharmacology | 1915 | |||
| rxnorm | EPOPROSTENOL SODIUM | FLOLAN | EPOPROSTENOL | |
| ChEBI | 15552 | |||
| ZINC | ZINC000003813078 |
